Objective： To observe the effect of Kaixin Capsule （开心胶囊, KXC） on myocardial ischemia and plasma endothelin （ET） level in patients with diabetic heart disease （DHD）. Methods： The 72 subjects for observatio...Objective： To observe the effect of Kaixin Capsule （开心胶囊, KXC） on myocardial ischemia and plasma endothelin （ET） level in patients with diabetic heart disease （DHD）. Methods： The 72 subjects for observation were randomly selected from inpatients whose diagnosis fit to the standard of DHD. The 32 patients allocated in the control group were treated with conventional Western medicine, and the 40 patients in the treated group were treated with conventional Western medicine in combination with KXC, with the therapeutic course for both groups as 60 days. Results： On ECG, the total effective rate and markedly ef- fective rate in the treated group was 85. 0% and 37. 5% respectively, higher than those in the control group＇s 68.7% and 28. 1% respectively, and showing significant difference between the two groups （P〈 0.05）. The level of ET in patients in both groups was significantly higher than normal range, after treatment, but reduced to different extent, and the comparison between them also showed that the difference was significant （P〈0.05）. Conclusion： KXC might, by way of inhibiting and blocking the release of ET, lower its level in plasma so as to improve the myocardial ischemic condition of patients with DHD.展开更多
文摘Objective： To observe the effect of Kaixin Capsule （开心胶囊, KXC） on myocardial ischemia and plasma endothelin （ET） level in patients with diabetic heart disease （DHD）. Methods： The 72 subjects for observation were randomly selected from inpatients whose diagnosis fit to the standard of DHD. The 32 patients allocated in the control group were treated with conventional Western medicine, and the 40 patients in the treated group were treated with conventional Western medicine in combination with KXC, with the therapeutic course for both groups as 60 days. Results： On ECG, the total effective rate and markedly ef- fective rate in the treated group was 85. 0% and 37. 5% respectively, higher than those in the control group＇s 68.7% and 28. 1% respectively, and showing significant difference between the two groups （P〈 0.05）. The level of ET in patients in both groups was significantly higher than normal range, after treatment, but reduced to different extent, and the comparison between them also showed that the difference was significant （P〈0.05）. Conclusion： KXC might, by way of inhibiting and blocking the release of ET, lower its level in plasma so as to improve the myocardial ischemic condition of patients with DHD.
